Evidence map›Paper›PMID 31805552›Full record

ArticleJournal of innate immunity2020

Siglec-14 Enhances NLRP3-Inflammasome Activation in Macrophages.

Chih-Ming Tsai, Angelica M Riestra, Syed Raza Ali, Jerry J Fong, Janet Z Liu, Gillian Hughes, Ajit Varki, Victor Nizet

Open access · goldAbstract read
In one paragraph

Article in Journal of innate immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Lysosomal permeabilization by Group AInfection and immunity · 2026
    Article
  6. Article
  7. Review
  8. Siglecs: From Biomodulation to Immunotherapy.Current protein & peptide science · 2026
    Review
  9. Review
  10. Article
  11. Lysosomal permeabilization by Group AbioRxiv : the preprint server for biology · 2025
    Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Chih-Ming TsaiGlycobiology Research and Training Center, UC San Diego, La Jolla, California, USA.
Angelica M RiestraCollaborative to Halt Antibiotic-Resistant Microbes, Department of Pediatrics, UC San Diego, La Jolla, California, USA.
Syed Raza AliGlycobiology Research and Training Center, UC San Diego, La Jolla, California, USA.
Jerry J FongGlycobiology Research and Training Center, UC San Diego, La Jolla, California, USA.
Janet Z LiuGlycobiology Research and Training Center, UC San Diego, La Jolla, California, USA.
Gillian HughesCollaborative to Halt Antibiotic-Resistant Microbes, Department of Pediatrics, UC San Diego, La Jolla, California, USA.
Ajit VarkiGlycobiology Research and Training Center, UC San Diego, La Jolla, California, USA.
Victor NizetGlycobiology Research and Training Center, UC San Diego, La Jolla, California, USA, vnizet@ucsd.edu.
University of California, San Diego · USLa Jolla Institute For Molecular Medicine · US

Funding

UCSD/SDSU IRACDAK12GM068524 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TREJO, JOANN · 2003 to 2025
$24.4M
Siglec Modulation of Inflammatory ResponsesP01HL107150 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LE, DZUNG T · 2011 to 2017
$18.0M
NHLBI NIH HHS P01 HL107150NIGMS NIH HHS K12 GM068524
6 · The paper itself

Abstract

Pathogenic microorganisms are sensed by the inflammasome, resulting in the release of the pro-immune and proinflammatory cytokine interleukin-1β (IL-1β). In humans, the paired <underline>s</underline>ialic acid-binding Ig-like lectin receptors Siglec-5 (inhibitory) and Siglec-14 (activating) have been shown to have reciprocal roles in regulating macrophage immune responses, but their interaction with IL-1β signaling and the inflammasome has not been characterized. Here we show that in response to known inflammasome activators (ATP, nigericin) or the sialic acid-expressing human bacterial pathogen group B Streptococcus (GBS), the presence of Siglec-14 enhances, whereas Siglec-5 reduces, inflammasome activation and macrophage IL-1β release. Human THP-1 macrophages stably transfected with Siglec-14 exhibited increased caspase-1 activation, IL-1β release and pyroptosis after GBS infection, in a manner blocked by a specific inhibitor of nucleotide-binding domain leucine-rich repeat protein 3 (NLRP3), a protein involved in inflammasome assembly. Another leading pathogen, Streptococcus pneumoniae, lacks sialic acid but rather prominently expresses a sialidase, which cleaves sialic acid from macrophages, eliminating cis- interactions with the lectin receptor, thus attenuating Siglec-14 induced IL-1β secretion. Vimentin, a cytoskeletal protein released during macrophage inflammatory activation is known to induce the inflammasome. We found that vimentin has increased interaction with Siglec-14 compared to Siglec-5, and this interaction heightened IL-1β production by Siglec-14-expressing cells. Siglec-14 is absent from some humans because of a SIGLEC5/14 fusion polymorphism, and we found increased IL-1β expression in primary macrophages from SIGLEC14+/+ individuals compared to those with the SIGLEC14-/+ and SIGLEC14-/- genotypes. Collectively, our results identify a new immunoregulatory role of Siglec-14 as a positive regulator of NLRP3 inflammasome activation.

Indexed as

HumansInflammasomesLectinsMacrophagesNLR Family, Pyrin Domain-Containing 3 ProteinReceptors, Cell SurfaceStreptococcal InfectionsStreptococcus agalactiaeTHP-1 CellsInflammasomesLectinsNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanReceptors, Cell SurfaceSIGLEC14 protein, humanCaspase-1InflammasomeInnate immunityInterleukin-1βMacrophagesSiglecVimentin

Identifiers

PMID31805552
PMCPMC7383293
OpenAlexW2993415519

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.